Post-cardiac arrest myocardial dysfunction (PCAMD) is a frequent complication faced during postresuscitation care that adversely impacts survival and neurological outcome. Both mechanical and electrical factors contribute to the occurrence of PCAMD. Pre-arrest ventricular function, the cause of cardiac arrest, global ischaemia, resuscitation factors, ischaemia/reperfusion injury and postresuscitation treatments contribute to the severity of PCMAD. The pathophysiology of PCAMD is complex and include myocytes energy failure, impaired contractility, cardiac oedema, mitochondrial damage, activation of inflammatory pathways and the coagulation cascade, persistent ischaemic injury and myocardial stiffness.Hypotension and low cardiac output with vasopressor/inotropes need are frequent after resuscitation. However, clinical, hemodynamic and laboratory signs of shock are frequently altered by cardiac arrest pathophysiology and post-resuscitation treatment, potentially being misleading and not fully reflecting the severity of post-cardiac arrest syndrome. Even if validated criteria are lacking, an extensive haemodynamic evaluation is useful to define a "benign" and a "malign" form of myocardial dysfunction and circulatory shock, potentially having treatment and prognostic implications. Cardiac output is frequently decreased after cardiac arrest, particularly in patients treated with target temperature management (TTM); however, it's not independently associated with outcome. Sinus bradycardia during TTM seems independently associated with survival and good neurological outcome, representing a promising prognostic indicator. Higher mean arterial pressure (MAP) seems to be associated with improved survival and cerebral function after cardiac arrest; however, two recent randomized clinical trials failed to replicate these results.Recommendations on haemodynamic optimization are relatively poor and are largely based on general principle of intensive care medicine.